BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30957798)

  • 1. Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin.
    Lee VEY; Chin CF; Ang WH
    Dalton Trans; 2019 Jun; 48(21):7388-7393. PubMed ID: 30957798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
    Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
    Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design.
    Zhang JZ; Bonnitcha P; Wexselblatt E; Klein AV; Najajreh Y; Gibson D; Hambley TW
    Chemistry; 2013 Jan; 19(5):1672-6. PubMed ID: 23255183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
    Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What do we know about the reduction of Pt(IV) pro-drugs?
    Wexselblatt E; Gibson D
    J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
    Lee KGZ; Babak MV; Weiss A; Dyson PJ; Nowak-Sliwinska P; Montagner D; Ang WH
    ChemMedChem; 2018 Jun; 13(12):1210-1217. PubMed ID: 29637702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.
    Göschl S; Varbanov HP; Theiner S; Jakupec MA; Galanski MS; Keppler BK
    J Inorg Biochem; 2016 Jul; 160():264-74. PubMed ID: 27055943
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Lee VEY; Lim ZC; Chew SL; Ang WH
    Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
    Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D
    J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs.
    Shi H; Romero-Canelón I; Hreusova M; Novakova O; Venkatesh V; Habtemariam A; Clarkson GJ; Song JI; Brabec V; Sadler PJ
    Inorg Chem; 2018 Nov; 57(22):14409-14420. PubMed ID: 30365308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
    Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
    ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.
    Navas F; Chocarro-Calvo A; Iglesias-Hernández P; Fernández-García P; Morales V; García-Martínez JM; Sanz R; De la Vieja A; García-Jiménez C; García-Muñoz RA
    J Med Chem; 2024 Apr; 67(8):6410-6424. PubMed ID: 38592014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.
    Johnstone TC; Suntharalingam K; Lippard SJ
    Chem Rev; 2016 Mar; 116(5):3436-86. PubMed ID: 26865551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum(IV) Complexes of
    Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
    Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
    Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the Arsenal of Pt
    Yempala T; Babu T; Karmakar S; Nemirovski A; Ishan M; Gandin V; Gibson D
    Angew Chem Int Ed Engl; 2019 Dec; 58(50):18218-18223. PubMed ID: 31599054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
    Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy.
    Höfer D; Varbanov HP; Legin A; Jakupec MA; Roller A; Galanski MS; Keppler BK
    J Inorg Biochem; 2015 Dec; 153():259-271. PubMed ID: 26365319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
    Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.